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Abstract
There are more than 40 human papillomaviruses (HPVs) belonging to the alpha genus that cause sexually transmitted
infections; these infections are among the most frequent and can lead to condylomas and anogenital intra-epithelial
neoplasia. At least 18 of these viruses are causative agents of anogenital carcinomas. We evaluated the performance of a
resequencing microarray for the detection and genotyping of alpha HPV of clinical significance using cloned HPV DNA. To
reduce the number of HPV genotypes tiled on microarray, we used reconstructed ancestral sequences (RASs) as they are
more closely related to the various genotypes than the current genotypes are among themselves. The performance of this
approach was tested by genotyping with a set of 40 cervical smears already genotyped using the commercial PapilloCheck
kit. The results of the two tests were concordant for 70% (28/40) of the samples and compatible for 30% (12/40). Our
findings indicate that RASs were able to detect and identify one or several HPV in clinical samples. Associating RASs with
homonym sequences improved the genotyping of HPV present in cases of multiple infection. In conclusion, we
demonstrate the diagnostic potential of resequencing technology for genotyping of HPV, and illustrate its value both for
epidemiological studies and for monitoring the distribution of HPV in the post-vaccination era.
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Introduction
More than 170 human papillomavirus (HPVs) have been
characterized and they are classified into the alpha, beta, gamma,
mu, and nu genera [1]. Some alpha papillomaviruses presenting a
mucous tropism cause some of the most frequent sexually
transmitted infections: around 300 million women worldwide
carry a HPV infection of the uterine cervix. About 40 HPV
genotypes able to infect genital mucous membranes have been
identified. Low-risk mucosal HPVs (LR HPVs) are responsible for
condylomas found in 1–2% of the sexually active population.
High-risk HPVs (HR HPVs) are causative agents of more than
80% of high-grade cervical intra-epithelial neoplasia [2]. Persistent
lesions associated with HR HPVs may evolve towards invasive
cervical carcinomas. HPV DNA sequences are detected in the vast
majority of adenocarcinomas, adenosquamous carcinomas and
squamous cell carcinomas of the cervix, all of which are preceded
by premalignant lesions [3]. HR HPVs also contributes to the
pathogenesis of other anogenital and aero-digestive tract cancers
[4].
The need for effective screening for cervical cancer is now
recognized worldwide and testing for HPVs is a potentially
powerful approach to the detection of cervical or anogenital
lesions. Other than the hybrid capture II and the Cervista
detection tests [5], most of the available tests for HPVs are based
on PCR methods using degenerate or consensus primers. All these
methods allow the detection, and some allow genotyping, of a wide
spectrum of HPVs. In addition to their clinical value, robust
methods of detection are required for epidemiological studies of
HPV infections. In particular, they could be used to study the
prevalence and distribution of circulating HPV genotypes in
vaccinated and non-vaccinated populations.
Several low or high-density microarrays have been developed
and successfully used for the detection of several viral families such
as Papillomaviridae. Most of them are based on long oligonucle-
otide probes and virus identification is based only on hybridization
patterns. This approach leads to a lack of information for
pathogen identification at the single-pair resolution level [6,7].
However, this limitation has since been overcome with the use of
the resequencing microarrays (RMAs) method. Resequencing
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microarray (RMA) technology involves generating a DNA/RNA
sequence corresponding to the pathogen(s) present in a sample in a
single assay. It allows detection of a sequence with a tolerance of
divergence of up to 10–15% from those tiled on the microarray
[8,9,10]. We have previously used RMAs for the detection of a
large panel of viral and bacterial pathogens by resequencing the
hybridised DNA. This approach has been successfully applied to
diverse clinical situations such as the establishment of a rapid
laboratory diagnostic test for pandemic influenza viruses [11,12],
the characterization of different strains of the monkeypox virus
[13,14], the genotyping of several members of the Rhabdoviridae
family [8] and the identification and characterization of arbovi-
ruses and hemorrhagic fever viruses in biological samples [15,16].
The aim of this study was to develop a multiplex bioassay
method, based on RMA technology, for the detection of mucosal
HPV genotypes of public health importance. Because of the wide
genetic diversity of HPVs and to reduce the number of genotypes
tiled on the microarray, we inferred reconstructed ancestral
sequences (RASs); these sequences are more closely related to
different genotypes than such genotypes are to each other. The
advantages of using reconstructed ancestral sequences for RMAs
has been described and illustrated using pathogen identification
with Enterobacteriaceae rpoB sequences used as models [17]. We
went on to apply the RMA method developed to detection of HPV
DNA sequences in clinical samples.
Figure 1. Phylogenetic tree of 38 alpha HPV isolates, constructed to assess the resequencing microarray approach. The tree was
constructed from the 416–base sequences of part of the L1 ORF in the different HPVs. The tree was generated by the neighbor-joining method using
BioNumerics v5.10 software (Applied-Maths, Belgium). HPV sequences tiled on RMA (red squares), location of RASs on the tree (blue circles) and
cloned HPVs tested with RMAs (green triangles) are indicated.
doi:10.1371/journal.pone.0109301.g001
RMA for HPV Genotyping
PLOS ONE | www.plosone.org 2 November 2014 | Volume 9 | Issue 11 | e109301
Materials and Methods
Principle and content of resequencing microarray
A third generation resequencing microarray, named VirID
v3.0, containing 724 viral sequences distributed into 27 families
and 85 genera (Table S1), was used in this study. Among the many
viral sequences tiled, a set of 38 different HPV sequences was used.
The size of the tiled region ranged from 455 to 482 nucleotides
corresponding to part of the L1 open reading frame. This set
includes sequences in the following genotypes: HPV6, 11, 16, 18,
26, 30, 31, 33, 34, 35, 40, 42, 43, 44, 45, 51, 53, 54, 56, 58, 59, 65,
66, 67, 68, 69, 70, 73, 74, 82, 85, 88, 91, 95, 97, 101, 103 and 108.
In addition, ten reconstructed ancestral sequences (RASs) were
tiled on the microarray. These sequences are described in Tables
S1 and S2. For each sequence tiled, the principle of RMA is to
interrogate each single base of the unknown sequence to be
detected with a set of eight appropriate 25-mer probes. Two
probes among the eight (four for each sense of the selected
sequence) correspond to perfect matches at the central (13th)
position of the probe, and the other six probes represent all
possible mismatches at the same position.
Ancestral sequences reconstruction
RASs were designed based on phylogenetic analysis of
nucleotide sequences of a portion of 416 bases in the L1 ORF
of 38 alpha-HPV; there were neither insertions nor deletions in
this stretch. A neighbor-joining tree was obtained using software
BioNumerics v5.10 (Applied-Maths, Belgium). Ancestral sequenc-
es were reconstructed by maximum likelihood using the PAML v4
software [18]. The nucleotide substitution model used was K80
with gamma (number of categories of distinct substitution rates)
and kappa (transition/transversion ratio) parameters estimated.
Extraction and amplification of HPV DNA
Viral DNA was obtained from cloned HPV DNA and from
cervical smears provided by the National Reference Laboratory
for Human Papillomavirus at Institut Pasteur (Paris). The cloned
HPV DNA used for validation assays was amplified and purified as
previously described [19]. Total DNA was extracted from cervical
smears using the NucleoSpin Tissue extraction kit according to the
recommendations of the supplier (Macherey Nagel, Hoerdt,
France). Following extraction, samples were digested with
Plasmid-Safe DNase for 12 hours at 37uC according to the
manufacturer’s instructions to enrich for circular viral DNA
(Epicentre). All DNAs were amplified using the Repli-g Mini Kit
according to the manufacturer’s instructions (Qiagen). The
concentration of amplified DNAs was determined with the
Quant-it kit (Life technologies) and aliquots of 10 ug were used
for hybridization in RMA assays.
Ethical considerations
Liquid-based cytology (LBC) samples were collected from
women attending organized cervical screening in 16 pilot sites in
France. After completion of cytology, residual LBC samples were
anonymized and sent to the French HPV Reference Laboratory
for genotyping. The residual material would otherwise have been
discarded. According to French regulations of biomedical
research, a written or verbal informed consent and an ethical
approval are not required for such studies. However, the study was
given favorable ethical opinion by the Comite´ de Recherche
Clinique at the Institut Pasteur (Avis nu 200-51). The collection of
human samples was declared to the French Research Ministry
(nuDC-2010-1197, collection nu1) in accordance with French
regulations.
Hybridization on RMA and data analysis
Amplified DNA was fragmented and labeled using the
GeneChip Resequencing Assay Kit (Affymetrix Inc., Santa Clara,
CA). After overnight hybridization at 45uC, the RMA was washed,
stained and scanned according to Affymetrix’ instructions. The
raw image file (.DAT), obtained after the scan, was converted to a
fluorescence intensity file (.CEL). Bases were called by the
GeneChip Sequence Analysis Software (GSEQ v 4.1) which uses
a derivative of the ABACUS base-calling algorithm [20]. This
algorithm consists of an automated statistical method that analyses
raw RMA hybridization data and optimizes the base-calling
process. For each base-call, a quality score is calculated from the
difference between the best fitting model and the second best one.
If this score is below a chosen threshold, an undetermined base
‘‘N’’ is assigned to that position. Sequences were output in FASTA
Table 1. Resequencing microarray assays with cloned HPV DNA.
HPV species HPV genotype Call ratea (%) Accuracyb (%) BLAST scorec
a1 42 96.5 99.5 780
a5 51 94.4 99.3 749
a6 53 93.6 98.6 717
56 95.7 99.5 751
66 95.4 100 751
a7 18 94.5 99.5 765
45 94.2 99.8 764
a9 16 94.9 100 767
a10 6 94.7 100 758
11 94.4 100 738
a13 54 92.1 100 704
c 108 97.7 100 809
aRatio between the number of bases determined and the sequence length.
bRatio between the number of correctly determined bases and the total number of determined bases.
cThe score of the highest scoring high-scoring segment pair (HSP) from that database sequence.
doi:10.1371/journal.pone.0109301.t001
RMA for HPV Genotyping
PLOS ONE | www.plosone.org 3 November 2014 | Volume 9 | Issue 11 | e109301
T
a
b
le
2
.
Id
e
n
ti
fi
ca
ti
o
n
o
f
H
P
V
1
6
an
d
o
th
e
r
H
P
V
s
w
it
h
h
o
m
o
n
ym
o
u
s
an
d
n
o
n
h
o
m
o
n
ym
o
u
s
se
q
u
e
n
ce
s.
C
lo
n
e
d
H
P
V
te
st
e
d
1
6
6
6
1
6
+6
6
1
6
+6
6
+5
1
+1
0
8
S
p
e
ci
e
s
T
il
e
d
H
P
V
C
a
ll
ra
te
v
a
lu
e
a
N
B
la
st
sc
o
re
H
P
V
id
e
n
ti
fi
e
d
C
a
ll
ra
te
v
a
lu
e
a
N
B
la
st
sc
o
re
H
P
V
id
e
n
ti
fi
e
d
C
a
ll
ra
te
v
a
lu
e
a
N
B
la
st
sc
o
re
H
P
V
id
e
n
ti
fi
e
d
C
a
ll
ra
te
v
a
lu
e
a
N
B
la
st
sc
o
re
H
P
V
id
e
n
ti
fi
e
d
a
5
5
1
1
5
.2
N
e
g
N
.A
.
1
2
.8
N
e
g
N
.A
.
2
2
.5
N
e
g
N
.A
.
9
4
.4
7
4
9
5
1
8
2
1
8
.7
N
e
g
N
.A
.
1
3
.0
5
3
.6
6
6
2
1
.7
N
e
g
N
.A
.
4
5
.3
1
4
7
5
1
a
6
5
6
2
4
.1
N
e
g
N
.A
.
4
1
.4
1
3
4
6
6
4
6
.6
7
5
.2
6
6
4
6
.0
1
1
8
6
6
5
3
1
7
.1
N
e
g
N
.A
.
3
1
.9
5
9
6
6
3
4
.7
N
e
g
N
.A
.
3
8
.5
6
9
.8
6
6
6
6
2
8
.4
N
e
g
N
.A
.
9
5
.4
7
5
1
6
6
9
1
.3
6
7
7
6
6
9
5
.4
7
5
1
6
6
3
0
2
6
.9
5
1
.8
1
6
2
9
.9
1
0
1
6
6
4
1
.9
1
4
5
6
6
3
6
.9
2
0
5
6
6
a
7
4
5
2
1
.6
5
3
.6
1
6
1
2
.9
N
e
g
N
.A
.
2
5
.3
5
9
U
n
d
.
2
2
.4
6
0
.8
U
n
d
.
5
9
2
3
.9
4
4
.6
1
6
1
0
.3
N
e
g
N
.A
.
2
5
.6
N
e
g
N
.A
.
2
6
.4
4
1
1
6
a
9
1
6
9
4
.9
7
6
7
1
6
2
3
.1
7
7
6
6
9
0
.3
6
8
8
1
6
9
4
.9
7
6
7
1
6
3
3
2
5
.2
5
0
1
6
2
0
.7
4
4
.6
6
6
3
2
.4
4
4
.6
1
6
3
2
.6
9
4
.5
1
6
3
5
2
9
.6
N
e
g
N
.A
.
1
4
.8
5
9
6
6
3
3
.8
1
0
1
1
6
3
0
.8
6
4
.4
1
6
a
1
0
7
4
2
2
.8
4
6
.4
1
6
9
.8
N
e
g
N
.A
.
2
2
.9
4
4
.6
1
6
2
2
.6
4
8
.2
1
6
a
1
3
5
4
2
3
.3
4
4
.6
1
6
1
2
.7
N
e
g
N
.A
.
2
4
.4
4
6
.4
U
n
d
.
2
4
.6
5
0
U
n
d
.
c
6
1
0
8
1
8
.1
N
e
g
N
.A
.
1
4
.1
N
e
g
N
.A
.
1
8
.9
N
e
g
N
.A
.
9
7
.7
8
0
9
1
0
8
a
R
at
io
b
e
tw
e
e
n
th
e
n
u
m
b
e
r
o
f
b
as
e
s
d
e
te
rm
in
e
d
an
d
th
e
se
q
u
e
n
ce
le
n
g
th
.
V
al
u
e
s
in
b
o
ld
co
rr
e
sp
o
n
d
to
th
e
ca
ll
ra
te
va
lu
e
,
N
B
la
st
sc
o
re
an
d
re
su
lt
o
f
B
LA
ST
o
f
H
P
V
s
te
st
e
d
w
it
h
th
e
h
o
m
o
n
ym
o
u
s
se
q
u
e
n
ce
.
N
e
g
:
N
e
g
at
iv
e
;
N
.A
:
N
o
t
ap
p
lic
ab
le
;
U
n
d
.:
U
n
d
e
te
rm
in
e
d
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
9
3
0
1
.t
0
0
2
RMA for HPV Genotyping
PLOS ONE | www.plosone.org 4 November 2014 | Volume 9 | Issue 11 | e109301
T
a
b
le
3
.
Id
e
n
ti
fi
ca
ti
o
n
o
f
H
P
V
1
8
an
d
o
th
e
r
H
P
V
s
w
it
h
h
o
m
o
n
ym
o
u
s
an
d
n
o
n
h
o
m
o
n
ym
o
u
s
se
q
u
e
n
ce
s.
C
lo
n
e
d
H
P
V
1
8
1
8
+4
5
1
8
+5
3
1
8
+5
3
+6
+4
2
S
p
e
ci
e
s
T
il
e
d
H
P
V
C
a
ll
ra
te
v
a
lu
e
a
N
B
la
st
sc
o
re
H
P
V
id
e
n
ti
fi
e
d
C
a
ll
ra
te
v
a
lu
e
a
N
B
la
st
sc
o
re
H
P
V
id
e
n
ti
fi
e
d
C
a
ll
ra
te
v
a
lu
e
a
N
B
la
st
sc
o
re
H
P
V
id
e
n
ti
fi
e
d
C
a
ll
ra
te
v
a
lu
e
a
N
B
la
st
sc
o
re
H
P
V
id
e
n
ti
fi
e
d
a
1
4
2
1
1
.2
N
e
g
N
.A
.
1
2
.5
N
e
g
N
.A
.
2
3
.5
N
e
g
N
.A
.
9
6
.6
7
8
0
4
2
a
6
5
3
4
N
e
g
N
.A
.
9
.5
N
e
g
N
.A
.
9
2
.7
7
0
2
5
3
9
3
.6
7
1
7
5
3
5
6
1
0
.6
N
e
g
N
.A
.
1
8
.0
N
e
g
N
.A
.
2
8
.0
4
6
.4
5
3
2
9
.5
4
1
5
3
a
7
1
8
9
6
.6
8
0
1
1
8
9
3
.7
7
5
1
1
8
8
9
.1
6
6
6
1
8
9
4
.5
7
6
5
1
8
4
5
4
7
.9
1
6
8
1
8
9
4
.2
7
6
4
4
5
3
1
.3
1
3
6
1
8
5
2
.9
2
0
4
1
8
5
9
2
0
.2
N
e
g
N
.A
.
2
7
.5
4
6
.4
U
n
d
.
1
7
.0
N
e
g
N
.A
.
2
6
.9
N
e
g
N
.A
.
6
8
2
0
.8
7
5
.2
1
8
2
8
.3
1
2
3
1
8
2
2
.7
5
7
.2
1
8
2
7
.8
1
2
8
1
8
7
0
2
1
.4
N
e
g
N
.A
.
3
1
.9
6
2
.8
4
5
2
3
.1
5
1
.8
5
3
3
1
.5
N
e
g
N
.A
.
9
7
4
1
.0
1
1
2
1
8
6
3
.0
2
6
2
4
5
2
9
.4
N
e
g
N
.A
.
5
1
.9
2
1
1
1
8
a
8
4
0
1
7
.2
N
e
g
N
.A
.
2
6
.0
N
e
g
N
.A
.
1
4
.3
N
e
g
N
.A
.
2
0
.0
N
e
g
N
.A
.
4
3
1
1
.5
N
e
g
N
.A
.
2
7
.7
5
5
.4
U
n
d
.
1
3
.2
N
e
g
N
.A
.
2
3
.0
4
2
.8
U
n
d
.
a
9
1
6
1
7
.1
4
6
.4
1
8
2
1
.8
5
1
.8
1
8
1
6
.9
N
e
g
N
.A
.
3
2
.6
7
7
6
3
1
1
5
.0
6
9
.8
1
8
2
3
.3
6
4
.4
U
n
d
1
9
.9
5
7
.2
5
3
2
8
.8
1
2
2
U
n
d
.
3
3
1
4
.5
N
e
g
N
.A
.
2
1
.7
5
0
1
8
1
9
.4
4
2
.8
5
3
2
6
.4
6
6
.2
6
3
5
1
6
.5
N
e
g
N
.A
.
2
5
.3
4
6
.4
1
8
1
7
.3
N
e
g
N
.A
.
3
8
.3
4
8
.2
4
2
5
8
1
0
.6
N
e
g
N
.A
.
1
6
.6
N
e
g
N
.A
.
1
3
.2
N
e
g
N
.A
.
2
0
.2
N
e
g
N
.A
.
6
7
2
3
.0
6
2
.6
1
8
2
6
.4
1
1
2
1
8
1
8
.9
N
e
g
N
.A
.
3
2
.1
9
8
.2
1
8
a
1
0
6
1
7
.4
5
4
.8
1
8
2
1
.3
6
0
.8
U
n
d
.
2
3
.0
N
e
g
N
.A
.
9
4
.7
7
5
8
6
a
1
1
7
3
1
5
.9
N
e
g
N
.A
.
1
9
.2
5
7
.2
1
8
1
3
.4
N
e
g
N
.A
.
2
9
.2
4
2
.8
1
8
a
1
3
5
4
2
1
.1
N
e
g
N
.A
.
2
8
.2
1
0
3
4
5
1
6
.8
N
e
g
N
.A
.
3
4
.1
N
e
g
N
.A
.
a
R
at
io
b
e
tw
e
e
n
th
e
n
u
m
b
e
r
o
f
b
as
e
s
d
e
te
rm
in
e
d
an
d
th
e
se
q
u
e
n
ce
le
n
g
th
.
V
al
u
e
s
in
b
o
ld
co
rr
e
sp
o
n
d
to
th
e
ca
ll
ra
te
va
lu
e
,
N
B
la
st
sc
o
re
an
d
re
su
lt
o
f
B
LA
ST
o
f
H
P
V
s
te
st
e
d
w
it
h
th
e
h
o
m
o
n
ym
o
u
s
se
q
u
e
n
ce
.
N
e
g
:
N
e
g
at
iv
e
;
N
.A
:
N
o
t
ap
p
lic
ab
le
;
U
n
d
.:
U
n
d
e
te
rm
in
e
d
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
9
3
0
1
.t
0
0
3
RMA for HPV Genotyping
PLOS ONE | www.plosone.org 5 November 2014 | Volume 9 | Issue 11 | e109301
format; for each HPV sequence obtained, the call rate value was
calculated as the ratio between the number of bases determined (A
or T or C or G) and the entire sequence length. The accuracy of
the RMA process was determined as the ratio between the number
of correctly determined bases and the total number of determined
bases, by comparison with the known sequence of the strains
tested.
Real-time PCR for HPV16 and HPV18
Quantitative PCR tests for HPV16 and HPV18 were performed
using DNA obtained from cervical smears (5 ul) or amplified
products (1/1000 dilution). The DNA was mixed with 100 pmol
of each primer (HPV16-for 59 GAACCGAAACCGGTTAGTA-
TAA 39; HPV16-rev 59 ATGTATAGTTGTTTGCAGCTC-
TGT 39; HPV18-for 59 GGACCGAAAACGGTGTATATAA
39; HPV18-rev 59 CAGTGAAGTGTTCAGTTCGGT 39) and
15 pmol of a probe (HPV16-probe 59 Fam-CATTTTATGCAC-
CAAAAGAGAACTGCAATGTTTC-BHQ139; HPV18-probe
59 Tamra ATGTGAGAAACACACCACAATACTATGGCGCG
BHQ2 39) in a final reaction volume of 20 ml, using a LC Taqman
Master kit (Roche Diagnostic, Inc.). The LightCycler qPCR assay
was performed as described by Schmitz et al. [21].
PapilloCheck HPV genotyping test
Clinical samples were tested using the PapilloCheck HPV
genotyping kit (Greiner BioOne, Frickenhausen, Germany). This
test involves PCR amplification with fluorescent primers (CY5
fluorophore) specific for the HPV E1 gene and the cellular
housekeeping gene ADAT1. The amplification products are then
hybridized to a DNA chip containing sequences for 18 high-risk
genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59,
66, 68, 70, 73, 82) and six low-risk genotypes (HPV 6, 11, 40, 42,
43 and 54/55). The PapilloCheck test was used according to the
recommendations of the supplier.
Results
1. Validation of RMA using cloned HPV DNA
The third generation of the ‘‘VirID’’ RMA (v3.0) was used for
the detection and identification of a broad panel of HPV
sequences. Thirty-eight HPV sequences were selected and tiled
on the microarray, including 32 from the a genus (HPV6, 11, 16,
18, 26, 30, 31, 33, 34, 35, 40, 42, 43, 44, 45, 51, 53, 54, 56, 58, 59,
66, 67, 68, 69, 70, 73, 74, 82, 85, 91, and 97) and covering all the
nine families found in cervical lesions and condylomas. The other
six sequences belonged to the c genus (HPV65, 88, 95, 101, 103,
and 108). Reconstructed Ancestral Sequences (RAS) were
designed through phylogenetic analysis of selected a genus
sequences. Sequences at nodes at different phylogenetic depths
on the tree were chosen as RASs (Fig. 1); we checked that all the
RASs selected branched directly or very closely to their respective
node, with near-zero branch lengths.
Of the 38 HPV sequences deposited on the chip, 11 a-HPV
sequences and one c-HPV sequence were tested using cloned
HPV genomes (Table 1): all the 12 sequences were detected with
call rate values between 92.1 and 97.7%, with a resequencing
accuracy of 98.6 to 100%. Confirmation of the HPV genotype was
obtained following BLASTN analysis, with scores between 704 (for
HPV54) to 809 (for HPV108) (Table 1).
2. Genotyping of HPVs with homonymous sequences
Because several sequences were tiled on the chip, we tested
whether each HPV genotype could be detected following
hybridization either to its homonymous sequence, or to related
sequences belonging to the same or different species. Various
cloned HPVs were tested, alone or in mixtures with HPVs
belonging to the same or different species (Tables 2 and 3).
HPV16 and HPV66 were perfectly identified by their homony-
mous sequences, whether they were on their own or in mixtures;
they were both identified by non-homonymous sequences,
including HPV30 and HPV33. HPV66 was also detected by the
sequences of HPV53, HPV56 and HPV82, whereas HPV16 was
detected by the sequences of HPV45 and HPV59 (Table 2). With
a mixture of both HPV16 and HPV66, only the most closely
related HPV was detected by a non-homonymous sequence
(Table 2). HPV18 was tested alone and in mixtures with HPV45
or HPV53: the three viruses were perfectly detected by their
corresponding homonymous sequences. Moreover, they were
simultaneously identified by several other non-homonymous
sequences (Table 3): for example, when two HPVs belonging to
the same species (such as HPV18 and HPV45) were tested
together, no competition was observed for their identification
either by homonymous or related sequences. Mixtures containing
HPV16, 51, 66, and 108 (Table 2) or HPV6, 18, 42, and 53
(Table 3) were similarly studied, and in all cases the various HPVs
were distinguished and identified by both homonymous and non-
homonymous sequences.
Table 4. Identification of HPVs belonging to the a6 family based on homonymous and reconstructed ancestral sequences.
HPV tested
HPV sequence tiled on RMA 53 56 66
HPV53 Call ratea 93.6a 35.6 38.5
BLAST score 717 111 69.8
HPV56 Call ratea 29.5 95.7 46
BLAST score 41 751 118
HPV66 Call ratea 34.9 43.9 95.4
BLAST score 42.8 145 751
RAS_811 Call ratea 59.1 71.2 75.7
BLAST score 107 197 306
aThe call rate value for HPVs tested with its homonymous sequence is indicated in boldface.
doi:10.1371/journal.pone.0109301.t004
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3. HPV genotyping with reconstructed ancestral
sequences
We wanted to determine whether all HPVs belonging to a single
species could be detected with a RAS specific for this species.
Within any family, the RAS is more closely related to the
sequences of the various HPVs than the sequences of the HPVs
are to each other (data not shown). We tested HPV53, 56 and 66,
all members of species alpha 6, and call rates of 59.1 to 75.7 were
obtained with RAS-811 (Table 4). These values were much higher
than those observed with non-homonymous sequences: 29.5 to
46.0. BLAST analyses of all the sequences obtained confirmed the
identification of the genotypes in all cases.
We next investigated whether HPVs that belong to different
species could be identified with RASs. We tested a mixture of
HPV16, 51, 66 and 108 (mixture A) and one of HPV6, 18, 42 and
53 (mixture B) with reconstructed RASs tiled on the microarray
(Table 5). HPV16 belonging to the alpha 9 species was detected by
RASs of the same alpha 9 species (RAS 814 and 815) and by RASs
designed for the alpha 1 (RAS 806) or alpha 5 (RAS 812) species.
By contrast, the alpha 5 HPV51 and the alpha 6 HPV66 were only
detected with RASs corresponding to the same species (RAS 813
and RAS 811, respectively). Similarly, HPV18 that belongs to the
alpha 7 species was detected with two RASs of the same species
(RAS809 and 810). HPV6 that belongs to the alpha 10 species was
identified by RASs of the same (RAS 810) and other (RAS 814
and 815) species. HPV42 and 53 were detected by RASs of
families alpha 1 (RAS 806) and alpha 6 (RAS 811), respectively.
HPV18 and 45 were tested together, and each HPV was detected
by its corresponding RAS (RAS809 for HPV45 and RAS810 for
HPV18) without any ambiguity (data not shown). These findings
indicate that one single RAS can detect and identify several HPVs;
however, the association of RASs with the homonym sequences
improved the genotyping of HPVs on their own or in mixtures.
4. Detection and genotyping of HPVs in clinical samples
by RMAs
We assessed whether this RMA method could be used to identify
HPVs in clinical samples. A set of 40 DNAs extracted from cervical
smears with normal (n= 3) and abnormal (8 Atypical Squamous
Cells of Unknown Significance (ASC-US), 1 Atypical squamous
cells cannot exclude HSIL (ASC-H), 11 Low-grade Squamous
Intraepithelial Lesion (LSIL) and 17 High-grade Squamous
Intraepithelial Lesion (HSIL)) cytology were provided by the French
HPV Reference Laboratory (Table 6). For each sample, the HPV
status was first determined with the PapilloCheck genotyping kit.
Most of the samples contained HPV16 or HPV18 on their own or
with other LR or HRHPVs. The copy number per cell was between
0.001 and 71 for HPV16 and 2 and 362 for HPV18, as determined
by quantitative real-time PCR (Table 6). The DNA preparations
were treated with PlasmidSafe DNase and amplified with phi29
polymerase, and then subjected to genotyping by RMAs with
homonymous sequences and RASs. All assays with the Papillo-
Check genotyping kit and RMAs were performed only one time
except with sample nu2012-312. This DNA was independently
amplified and hybridized on RMAs three times. Call rate and
standard deviation (SD) values for HPV16 were determined with
homonymous, non- homonymous and reconstructed ancestral
sequences. SD values ranged from 0.9 to 1.9% according to the
kind of considered sequences and were similar to values obtained
with a triplicate assay using cloned HPV16 DNA (table 7).
The PapilloCheck genotyping kit can detect and identify 18 HR
HPV (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66,
68, 70, 73, 82) and six LR HPV (HPV 6, 11, 40, 42, 43 and 54/
T
a
b
le
5
.
Id
e
n
ti
fi
ca
ti
o
n
o
f
H
P
V
s
b
y
re
co
n
st
ru
ct
e
d
an
ce
st
ra
l
se
q
u
e
n
ce
s.
R
e
co
n
st
ru
ct
e
d
a
n
ce
st
ra
l
se
q
u
e
n
ce
s
ti
le
d
o
n
th
e
m
ic
ro
a
rr
a
y
a
M
ix
tu
re
H
P
V
G
e
n
o
ty
p
e
(s
p
e
ci
e
s)
8
0
5
(a
8
)
8
0
6
(a
1
)
8
0
8
(a
1
0
)
8
0
9
(a
7
)
8
1
0
(a
7
)
8
1
1
(a
6
)
8
1
2
(a
5
)
8
1
3
(a
5
)
8
1
4
(a
9
)
8
1
5
(a
9
)
A
1
6
(a
9
)
4
3
.3
b
5
9
.9
b
5
7
b
3
9
.9
b
5
1
(a
5
)
8
8
.9
b
6
6
(a
6
)
7
5
.7
b
1
0
8
(c
6
)
B
6
(a
1
0
)
5
4
.3
b
4
8
.6
b
4
5
.7
b
1
8
(a
7
)
5
4
.1
b
7
9
.6
b
4
2
(a
1
)
5
1
.7
b
5
3
(a
6
)
9
9
.1
b
a
T
h
e
sp
e
ci
e
s
co
rr
e
sp
o
n
d
in
g
to
th
e
R
A
S
is
g
iv
e
n
in
p
ar
e
n
th
e
si
s.
b
T
h
e
ca
ll
ra
te
va
lu
e
fo
r
e
ac
h
R
A
S
is
in
d
ic
at
e
d
w
h
e
n
a
se
q
u
e
n
ce
w
as
id
e
n
ti
fi
e
d
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
9
3
0
1
.t
0
0
5
RMA for HPV Genotyping
PLOS ONE | www.plosone.org 7 November 2014 | Volume 9 | Issue 11 | e109301
Table 6. Genotyping of HPV from cervical smears using the PapilloCheck kit and resequecing microarray.
HPV identifiedc
Samples Cytologya copy/cell
b
Papillocheck Resequencing Microarray (RMA)
HPV16 HPV18
Based on homonyme
sequences
Based on reconstructed
ancestral sequences
2012-1557 N Neg Neg Neg
2012-1558 N Neg Neg Neg
2012-1559 N Neg Neg Neg
2012-1930 ASCUS Neg Neg Neg
2012-1931 ASCUS Neg 103 Neg
2012-620 ASCUS 1.6 16 16 16
2012-277 ASCUS 1.7 16, 42, 56 16, 42, 56 16, 42
2012-1660 ASCUS 35, 45, 53, 56 30, 35, 45, 53, 56, 67, 73 35, 45, 53
2012-1649 ASCUS 6, 39, 42, 44/55, 45 6, 42, 45, 55, 101 6, 42, 45, 55
2012-1620 ASCUS 40, 43, 44/55, 52, 56 40, 43, 52, 55, 56 43, 52, 55, 56
2012-1642 ASCUS 40, 42, 51, 53, 59, 73 35, 40, 42, 51, 53, 59, 67, 73 40, 42, 51, 53, 59, 67, 73
2012-249 ASC-H 0.9 16 16 16
2012-328 LSIL 0.5 16 16 16
2012-146 LSIL 361.5 18 18, 54, 74 18, 54, 74
2012-133 LSIL 11.3 18 18 18
2012-352 LSIL 4.2 16, 35 16, 35, 67 16, 43, 67
2012-354 LSIL 84 16, 39 16, 34, 39 16, 39
2012-601 LSIL 2.9 18, 33, 66 18, 33, 66 18, 33, 66
2012-351 LSIL 3.02 16, 33, 52, 66 16, 34, 66 16, 34, 66
2012-1940 LSIL 40, 42, 52, 66 30, 40, 42, 52, 54, 66, 82, 91 40, 52, 82, 66
2012-1607 LSIL 42, 51, 53, 66 42, 51, 53, 66 42, 51, 66
2012-445 LSIL 21 16, 39, 42, 59, 66 16, 32, 39, 42, 59, 66 16, 39, 42, 59, 66
2012-1673 LSIL 33, 42, 51, 52, 66 42, 51, 52, 54, 66 51, 52, 66
2012-451 HSIL 0.81 16 16 16
2012-495 HSIL 0.47 16 16 16
2012-622 HSIL 3.7 16 16 16
2012-234 HSIL 3.6 16 16 16
2012-312 HSIL 2.6 16 16 16
2012-499 HSIL 5.0 16 16 16
2012-248 HSIL 2.1 18 18 18
2012-314 HSIL 0.8 16, 42 16 16
2012-243 HSIL 0.05 16, 56 16, 56 16, 56
2012-266 HSIL 0.001 16, 56 16, 56 16, 56
2012-610 HSIL 70.6 16, 56 16 16
2012-613 HSIL 4.02 16, 59 16, 54, 59 16, 59
2012-292 HSIL 3.06 16, 40, 42 16, 42 16
2012-1945 HSIL 39, 56, 66 54, 56, 66 39, 66
2012-453 HSIL 0.52 16, 33, 42, 59 16, 33, 59 16, 33
2012-504 HSIL 58.8 18, 39, 45, 52, 56, 59, 70 18, 39, 45, 56, 59 18, 52, 45, 56, 45
aASCUS: Atypical Squamous Cells of Unknown Significance; ASCH: Atypical squamous cells cannot exclude HSIL; LSIL: Low-grade Squamous Intraepithelial Lesion; HSIL:
High-grade Squamous Intraepithelial Lesion;
bAs determined by quantitative real-time PCR.
cNeg: Negative; HPV genotypes detected by RMA and unidentifiable by the PapilloCheck kit are indicated in bold; HPV genotypes not detected by at least one of the
two methods are underlined.
doi:10.1371/journal.pone.0109301.t006
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55). The two methods PapilloCheck genotyping and RMA
genotyping with homonymous sequences gave concordant results
for 28/40 (70%) of the samples, and compatible results (one or two
HPV missed by one or other method) for 12/40 (30%) of the
samples. A value of k = 0.36 was obtained with the kappa test in
interrogation of agreement between these two tests. PapilloCheck
did not detect some HPVs found by RMAs (HPV 35 in sample
2012-1642; HPV73 in sample 2012-1660; HPV82 in sample 2012-
1940); the RMAs did not detect some strains identified by
PapilloCheck (HPV39 in sample 2012-1649, HPV33 and HPV52
in sample 2012-351, HPV33 in sample 2012-1673, HPV42 in
samples 2012-314 and 2012-453, HPV56 in sample 2012-610,
HPV40 in sample 2012-292, and HPV52 and 70 in sample 2012-
504). RMAs allowed two closely related HPVs, HPV44 and 55, to
be distinguished and genotyped, although they are indistinguish-
able by PapilloCheck (samples nu 2012-1620 and 2012-1649). No
discordant result was observed (Table 6).
The RMA method with homonymous sequences appeared to be
highly sensitive: HPV16 was detected in a sample in which there
was only 1 copy per 1000 cells (sample 2012-266). Eighteen HPVs
not identifiable with the PapilloCheck genotyping kit were
detected by RMAs in 14 samples (indicated in boldface in
Table 6). In particular, two gamma HPVs (HPV 101 and 103)
were identified in samples 2012-1931 and 2012-1649; these HPVs
were first detected in cervico-vaginal smears [22].
HPV genotyping following RMAs by homonymous sequences
and RASs gave compatible results, although fewer HPVs were
identified with RASs, particularly when the number of HPVs
detected by homonymous sequences was high. However, in one
case, HPV39 first identified by PapilloCheck, was detected only by
RASs (sample 2012-1945) (Table 6).
Discussion
Multiple broad-spectrum PCR methods have been developed
for the detection of the alpha-HPV genus and most are based on
HPV sequences in the L1 open reading frame. Here, we show that
resequencing microarray (RMA) technology was feasible and
effective for genotyping human papillomaviruses, and is thus a
potentially valuable tool for epidemiology. We have demonstrated
that the use of homonymous HPV sequences and reconstructed
ancestral sequences (RASs), either separately or combined, allows
precise molecular identification of different HPV genotypes. We
validated the method first with cloned HPV DNA and
subsequently for detection of HPVs in clinical samples. The
RMA method used involved treatment of cellular DNA with
Plasmid-Safe DNase and the universal Phi 29-based amplification;
this methodology was highly sensitive for the genotyping of HPVs
in clinical samples, with a detection limit of one copy of HPV16
per 1000 cells.
This RMA method allows the detection and characterization of
HPV genotypes other than those tiled on the microarray. Indeed,
the call rate values were a function of the percentage of divergence
between the tiled sequence and the sequence present in the
sample. We found that there was no substantial loss of detection
signal when the tiled sequence diverged by up to 10–15% from the
sequence of the pathogen in the sample. Moreover, the RASs were
designed to minimizing the divergence between the tiled and the
viral sequences potentially present in clinical samples. Indeed, the
use of RASs allowed an improvement in the detection of several
HPVs. Nevertheless, the nucleotide diversity of HPV sequences is
substantial and not a single RAS was able to detect all the different
HPVs present in cases of multiple infections.
We compared this RMA method to a commercial HPV
genotyping kit. It must be stressed that clinical samples with more
than one HPV were intentionally selected to compare the two
methods. Some HPV types identified in clinical samples by the
RMA method were not identified by the PapilloCheck test. This
discrepancy is in part explained by the number of HPV genotypes,
limited to 24, which can be identified by the PapilloCheck test.
The HPVs detected by RMAs but not by PapilloCheck tests
include both LR HPVs (HPV 32, 34, 54, 74, and 91) and HR
HPVs (HPV30, 34, and 67). Also, HR HPV35, 73, and 82, found
in some clinical samples by RMAs, were not detected by the
PapilloCheck test. Conversely, HPV33, 39, 52, 56, and 70
identifiable in some samples by the PapilloCheck kit were not
found by the RMA method. This presumably reflects different
sensitivities of the two tests for some HPV genotypes.
Our study has some limitations. First, due to the substantial
genetic diversity of HPVs with more than 170 HPV genotypes
already identified [1], not all alpha or gamma HPVs were studied,
and HPVs belonging to beta, mu and nu genera were not studied.
Nevertheless we were able to identify HPV101 and 103 that belong
to the gamma 6 species, and that were initially detected in cervico-
vaginal smears [20]. To increase the coverage of the known HPV
diversity, and to facilitate detection of novel genotypes, the number
of RASs should be increased. Second, in the current approach, only
a part of the L1 gene for each HPV genotype was targeted and tiled
on the microarray. The L1 gene may be deleted from the virus
associated with some genital cancers, and this would lead to false
negative results. The E6 and E7 genes have been described to be
highly expressed in high-grade cervical lesions and cancer.
Therefore, new generation RMA tests could include sequences
corresponding to the E6 and E7 genes, and this would allow
detection of both viral DNA and transcripts.
Table 7. Repeatability of RMA assay with cloned HPV16 DNA and biological sample with HPV16 monoinfection.
HPV16
Cloned HPV DNA Sample n6312
HPV sequence tiled on RMA Call ratea Standard deviationb Call ratea Standard deviationb
Homonymous HPV16 89.6 2.2 91.4 1.6
Non-homonymous HPV30 29.2 0.45 26.1 0.9
HPV33 28.0 1.4 18.7 1.6
Reconstructed Ancestral Sequence RAS814 53 2.8 35.2 1.9
aRatio between the number of bases determined and the sequence length.
bMicroarray assays were done in triplicate.
doi:10.1371/journal.pone.0109301.t007
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The cost of a high-density microarray could appear as a limit
because this technology required the synthesis of a physical mask.
However, the final cost can decrease if the demand increases, as
may be the case in the context of a clinical diagnostic use.
Moreover, the use of a RMA of the smallest size only dedicated to
detect and characterize HPVs will help to reduce the global cost of
assay. Adding of supplementary homonyms and reconstructed
ancestral sequences will allow developing countries to obtain a
better tool for the screening of HPVs. Based on the sequences
obtained, RMAs may be useful for molecular epidemiological
studies of HPV infection, particularly in geographical areas where
the distribution of circulating genotypes has not yet been
investigated. It can be used to identify variants of HPV genotypes
that differ from the prototype until 10–15%. RMA-based tests
may thus be informative about the prevalence and distribution of
diverse HPV genotypes in the post-vaccination era.
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